About: Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 1999

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 1999 (uk) im Januar 1999 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xineru de 1999 (ast) artikull shkencor i botuar më 01 janar 1999 (sq) scientific article published on 01 January 1999 (en)
publication date	wds:Q77733253-14E2047E-9813-4ABA-A25F-9926D4DBC3B4
publication date	1999-01-01 00:00:00Z (xsd:dateTime)
exact match	wds:Q77733253-F3F92CD7-EAB8-43D0-B804-911E3B539F14
exact match	https://scigraph.springernature.com/pub.10.1007/s002800050923
author name string	wds:Q77733253-14AF453E-E359-4585-9502-27DC0D5E196A wds:Q77733253-19A70FB7-DDA0-49BF-8B90-1CAE0B1E55FF wds:Q77733253-1EB9137F-A07C-43C3-AACF-C9567D4F7B69 wds:Q77733253-4F690738-C647-4876-96E4-192C843A9919 wds:Q77733253-5350EF2C-D068-42AB-B5F2-7BD1E9732456 wds:Q77733253-7C7E94FC-B614-458C-89B7-FDF0C0EA0F2B wds:Q77733253-8FF96F13-7F11-4DC4-A286-95BADEB4A21D wds:Q77733253-C5853892-F155-4452-ADDD-35FB7A451E7A wds:Q77733253-D445EE0D-3A07-49AD-BA3D-416F13871A22 wds:Q77733253-FD79F940-FD2F-4867-8357-E04F0016EC7A wds:Q77733253-FD8C4530-C03A-481B-8C7A-BF047839A1DD
author name string	Heideman RL Stewart CF Pratt CB Houghton PJ Pappo AS Meyer WH Bowman LC Tan M Santana VM Gajjar AJ Zamboni WC
rdfs:label	Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors (en) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors (nl) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors (sq)
skos:prefLabel	Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors (en) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors (nl) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors (sq)
name	Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors (en) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors (nl) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors (sq)
title	wds:Q77733253-5DD70EBC-73B7-4C32-8811-221DEF132019
title	Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors (en)
page(s)	wds:Q77733253-24C8C92B-6E4C-41F8-AC4F-AB603516F10D
page(s)	454-460
instance of	wds:Q77733253-97B2E7C6-07E8-475F-AC12-6BADFAEF9483
instance of	scholarly article
PubMed ID	wds:Q77733253-E271D8A9-5E89-4EFB-ABEC-490D6EBB190A
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10321504
PubMed ID	10321504
published in	wds:Q77733253-DE29828B-8F13-4A9D-9984-51E4E020A6C0
published in	Cancer Chemotherapy and Pharmacology
issue	wds:Q77733253-AD63484A-3733-49C8-BD90-F4B4D4C73D7B
volume	wds:Q77733253-C121D859-B273-4F39-A301-333361695E8C
issue	6
volume	43
DOI	wds:Q77733253-EDFC207B-6836-4965-B6DB-2C15CCF6E893
DOI	http://dx.doi.org/10.1007/S002800050923
DOI	10.1007/S002800050923
Dimensions Publication ID	wds:Q77733253-B7829E81-D3D3-4977-AC25-54A2D0F7534F
Dimensions Publication ID	1001757342
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q77733253
is cites work of	Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study Topotecan: a review of its efficacy in small cell lung cancer Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. Toxicity study of a new camptothecin anti-cancer agent CKD-602 in dogs: 4-week continuous intravenous dose by infusion pump and 4-week repeated intravenous dose Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant [Topotecan for pediatric patients with resistant and recurrent solid tumors] Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse An HPLC assay for the lipophilic camptothecin analog AR-67 carboxylate and lactone in human whole blood Metabolic pathways of the camptothecin analog AR-67 Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats In-vitro Cellular Uptake and Transport Study of 9-Nitrocamptothecin PLGA Nanoparticles Across Caco-2 Cell Monolayer Model
is cites work of	wds:Q33387815-125531EA-487D-4756-A0A1-C080E7F332F7 wds:Q37062610-3D146B1B-D356-44EB-AF92-4AEC821696EC wds:Q46981846-8A5D3AD0-7979-4B4A-B509-34EA02E5A432 wds:Q50353862-8993E744-29E1-4194-A675-3600BD88647E wds:Q35565630-DB2B1EDB-F7FE-45C3-8278-0F5FCC961CB3 wds:Q46967012-E6226AA0-251F-4D69-B842-2AA84DEA9ACE wds:Q40488652-637AB39B-2C61-4DFB-A30D-F6E8FA526732 wds:Q35046472-192218E3-8420-4C33-BF9B-6799502F3EF0 wds:Q44076450-844D7246-98B0-4443-AE46-89AE561119E7 wds:Q44562350-7B313CCB-6969-4888-9092-BD19DB9DFEB0 wds:Q46463187-106C6754-5322-4F09-B459-850A50F0D50F wds:Q33330077-CB581DF8-B01D-4BCA-A1B9-25DB5FB0318E wds:Q42988457-864A29AD-88F2-43A0-8934-58621955340D wds:Q44837135-B991FB3E-F165-4DE2-B6DC-AF2CE1F709FA wds:Q33696187-FA6DE4BE-3C7C-4C23-B481-08E3201410D1 wds:Q34715481-05337810-B0A8-4864-BF32-7C7346D3843F wds:Q51355553-D4AE4A47-89BC-4D3C-80F3-A30A15A22825

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software